Process evaluation and early outcomes of real-world implementation of a pharmacist-driven cabotegravir/rilpivirine long-acting injectable initiative

被引：1
|
作者：
Derrick, Caroline B. [1 ]
Magee, Matthew [2 ]
Tsai, Y. Vivian [3 ]
Pizzuti, Morgan E. [4 ]
Parker, Sarah [2 ]
Lucas, Omar [1 ]
Taylor, Kara [5 ]
Albright, Raeghan [6 ]
Langehans, Briley [7 ]
Schreiber, Danny [8 ]
Guest, Georgia [8 ]
Ahuja, Divya [1 ]
Weissman, Sharon [1 ]
机构：
[1] SC Univ South Carolina, Sch Med Columbia, Prisma Hlth Richland Columbia, Columbia, SC 29208 USA
[2] Univ South Carolina, Sch Med Columbia, Columbia, SC USA
[3] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[4] Prisma Hlth Richland Columbia, Columbia, SC USA
[5] WakeMed Hlth Raleigh, Raleigh, NC USA
[6] Publix Pharm Columbia, Columbia, SC USA
[7] Trident Med Ctr Charleston, Charleston, SC USA
[8] Univ South Carolina, Coll Pharm Columbia, Columbia, SC USA
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2024年
关键词：
cabotegravir; HIV-1; human immunodeficiency virus; pharmacist; resistance; rilpivirine; VIROLOGICAL FAILURE; HIV-1; INFECTION; RILPIVIRINE;
D O I：
10.1093/ajhp/zxae260
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain
    Antonio Garcia-Carmona, Juan
    Simal-Aguado, Jorge
    Pilar Campos-Navarro, Maria
    Valdivia-Munoz, Francisco
    Galindo-Tovar, Alejandro
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (01) : 18 - 24
  • [32] Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV
    Thoueille, Paul
    Saldanha, Susana Alves
    Schaller, Fabian
    Choong, Eva
    Veuve, Francois
    Munting, Aline
    Cavassini, Matthias
    Braun, Dominique
    Gunthard, Huldrych F.
    Ramirez, Jessy J. Duran
    Surial, Bernard
    Furrer, Hansjakob
    Rauch, Andri
    Ustero, Pilar
    Calmy, Alexandra
    Stockle, Marcel
    Di Benedetto, Caroline
    Bernasconi, Enos
    Schmid, Patrick
    Marzolini, Catia
    Girardin, Francois R.
    Buclin, Thierry
    Decosterd, Laurent A.
    Guidi, Monia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [33] Early HIV Infection Diagnostic Challenges in Injectable Long-Acting Cabotegravir Implementation in Routine Public Health PrEP Service in Zambia
    Mulenga, L.
    Phiri, C.
    Chisenga, T.
    Zyambo, K.
    Sivile, S.
    Bwalya, I.
    Musokotwane, K.
    Mwansa, M.
    Siame, M.
    Fwoloshi, S.
    Mzyece, J.
    Mwitumwa, M.
    Kampilimba-Mwango, L.
    Ndhlovu, A.
    Kawanga, L.
    Kampamba, D.
    Tambatamba, B.
    Nsama, D.
    Musonda, M.
    Lishimpi, K.
    Sinyangwe, G.
    Hachaambwa, L.
    Siwingwa, M.
    Mutukwa, J.
    Chitembo, L.
    Claassen, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 92 - 93
  • [34] Six-month outcomes of every 2-months long-acting cabotegravir and rilpivirine in a real-world setting: effectiveness, adherence to injections and patient-reported outcomes from PLWHIV in the German CARLOS cohort
    Borch, J.
    Scherzer, J.
    Jonsson-Oldenbuettel, C.
    Weinberg, G.
    Wyen, C.
    Rodriguez, E.
    Scholten, S.
    Dakhia, S.
    Dymek, K.
    Westermayer, B.
    Bernhardt, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 20 - 21
  • [35] Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
    John Lauriello
    Peter J. Weiden
    Carole D. Gleeson
    Ankit Shah
    Luke Boulanger
    Krutika Jariwala-Parikh
    Elizabeth Hedgeman
    Amy K. O’Sullivan
    CNS Drugs, 2021, 35 : 1123 - 1135
  • [36] Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
    Lauriello, John
    Weiden, Peter J.
    Gleeson, Carole D.
    Shah, Ankit
    Boulanger, Luke
    Jariwala-Parikh, Krutika
    Hedgeman, Elizabeth
    O'Sullivan, Amy K.
    CNS DRUGS, 2021, 35 (10) : 1123 - 1135
  • [37] Long-acting injectable Cabotegravir (CAB-LA) pilot implementation at primary healthcare level in resource-limited settings: Early real-world evidence from the USAID DISCOVER-Health Project in Zambia
    Ndhlovu, A. P.
    Kawanga, L.
    Phiri, D.
    Nyumbu, M.
    Musonda, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27
  • [38] Real-World Effectiveness of Long-Acting Injectable and Oral Antipsychotic Agents in US Medicare Patients with Schizophrenia
    Li, Pengxiang
    Geng, Zhi
    Benson, Carmela
    Patel, Charmi
    Doshi, Jalpa A.
    ADVANCES IN THERAPY, 2025, 42 (02) : 1251 - 1264
  • [39] PrEP15-19 Choices: an implementation study protocol of HIV prevention with oral and long-acting injectable cabotegravir PrEP in real-world settings among sexual and gender minority adolescents in Brazil
    Dourado, Ines
    Dezanet, Lorenza
    Magno, Laio
    Westin, Mateus
    Soares, Fabiane
    Massa, Paula
    Zucchi, Eliana Miura
    Rossi, Thais Regis Aranha
    Caires, Priscilla
    Vasconcelos, Ricardo de Paula
    Couto, Marcia Thereza
    Tupinambas, Unai
    Greco, Dirceu
    Grangeiro, Alexandre D.
    BMJ OPEN, 2025, 15 (01):
  • [40] Perspectives on the acceptability, appropriateness, feasibility, barriers, and facilitators from patients receiving cabotegravir plus rilpivirine long-acting injectable treatment (CAB plus RPV LA): interim results from the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL)
    Hocqueloux, L.
    Gutner, C.
    DeMoor, R.
    Gill, M.
    Trehan, R.
    D'Amico, R.
    Tomkins, S.
    Schroeder, M.
    Bontempo, G.
    Ait-Khaled, M.
    Hadi, M.
    Anand, S. Bakhshi
    Low, E. L.
    Jeanmaire, E.
    Crusells Canales, M.
    Vandekerckhove, L.
    Bonnet, F.
    Olalla Sierra, J.
    Czarnogorski, M.
    HIV MEDICINE, 2021, 22 : 99 - 99
12345